Contents

REVIEW

1457  Nonalcoholic fatty liver disease shows significant sex dimorphism

Chen XY, Wang C, Huang YZ, Zhang LL

MINIREVIEWS

1473  Management of procedural pain in the intensive care unit


ORIGINAL ARTICLE

Clinical and Translational Research

1485  Effect of prior malignancy on the prognosis of gastric cancer and somatic mutation

Yin X, He XK, Wu LY, Yan SX

Retrospective Cohort Study

1498  Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer

Chen ZX, Li J, Liu WB, Zhang SR, Sun H

Retrospective Study

1508  Timing theory continuous nursing, resistance training: Rehabilitation and mental health of caregivers and stroke patients with traumatic fractures

Shen YL, Zhang QZ, Zhu LJ, Liu JH

1517  Effect of precise nursing service mode on postoperative urinary incontinence prevention in patients with prostate disease

Zheng XC, Luo TT, Cao DD, Cai WZ

1527  Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis


1536  Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key

Zhou QY

Observational Study

1548  Correlation of myopia onset and progression with corneal biomechanical parameters in children

Lu LL, Hu XJ, Yang Y, Xu S, Yang SY, Zhang CY, Zhao QY
META-ANALYSIS

1557 Intensive vs non-intensive statin pretreatment before percutaneous coronary intervention in Chinese patients: A meta-analysis of randomized controlled trials
Yang X, Lan X, Zhang XL, Han ZL, Yan SM, Wang WX, Xu B, Ge WH

CASE REPORT

1572 Giant nodular fasciitis originating from the humeral periosteum: A case report
Yu SL, Sun PL, Li J, Jia M, Gao HW

1580 Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report
Deng PB, Jiang J, Hu CP, Cao LM, Li M

1586 Submucosal protuberance caused by a fish bone in the absence of preoperative positive signs: A case report
Du WW, Huang T, Yang GD, Zhang J, Chen J, Wang YB

1592 Misdiagnosis of unroofed coronary sinus syndrome as an ostium primum atrial septal defect by echocardiography: A case report
Chen JL, Yu CG, Wang DJ, Chen HB

1598 Uncommon complication of nasoenteral feeding tube: A case report
Jiang YP, Zhang S, Lin RH

1602 Treatment of extracranial internal carotid artery dissecting aneurysm with SUPERA stent implantation: Two case reports
Qiu MJ, Zhang BR, Song SJ

1609 Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report
Wang J, Gao YS, Xu K, Li XD

1617 Hemangioma in the lower labial vestibule of an eleven-year-old girl: A case report
Aloyoumy AT, Alsaifi AJ, Aladhyani SM, Alishalan AA, Alfayadh HM, Salem HM

1623 Primary orbital monophasic synovial sarcoma with calcification: A case report
Ren MY, Li J, Li RM, Wu YX, Han RJ, Zhang C

1630 Small-cell carcinoma of the prostate with negative CD56, NSE, Syn, and CgA indicators: A case report

1639 Disseminated peritoneal leiomyomatosis with malignant transformation involving right ureter: A case report
Wen CY, Lee HS, Lin JT, Yu CC
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1645</td>
<td>Arthroscopic surgery for synovial chondroma of the subacromial bursa with non-traumatic shoulder subluxation complications: Two case reports</td>
<td>Tang XF, Qin YG, Shen XY, Chen B, Li YZ</td>
</tr>
<tr>
<td>1667</td>
<td>Gastric schwannoma misdiagnosed as gastrointestinal stromal tumor by ultrasonography before surgery: A case report</td>
<td>Li QQ, Liu D</td>
</tr>
<tr>
<td>1675</td>
<td>Giant retroperitoneal lipoma presenting with abdominal distention: A case report and review of the literature</td>
<td>Chen ZY, Chen XL, Yu Q, Fan QB</td>
</tr>
<tr>
<td>1684</td>
<td>Pneumothorax during retroperitoneal laparoscopic partial nephrectomy in a lupus nephritis patient: A case report</td>
<td>Zhao Y, Xue Q, Xia D, Xu WF, Liu GH, Xie Y, Ji ZG</td>
</tr>
<tr>
<td>1689</td>
<td>Bulbar conjunctival vascular lesion combined with spontaneous retrobulbar hematoma: A case report</td>
<td>Lei JY, Wang H</td>
</tr>
<tr>
<td>1709</td>
<td>Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: Two case reports</td>
<td>Zhu WJ, Da YW, Chen H, Xu M, Lu Y, Di L, Duo JY</td>
</tr>
<tr>
<td>1723</td>
<td>Unusual magnetic resonance imaging findings of brain and leptomeningeal metastasis in lung adenocarcinoma: A case report</td>
<td>Li N, Wang YJ, Zhu FM, Deng ST</td>
</tr>
<tr>
<td>1738</td>
<td>Neurothekeoma located in the hallux and axilla: Two case reports</td>
<td>Huang WY, Zhang YQ, Yang XH</td>
</tr>
</tbody>
</table>
Subclavian artery stenting via bilateral radial artery access: Four case reports

Qiu T, Fu SQ, Deng XY, Chen M, Dai XY
ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Prashanth Panta, MDS, Reader (Associate Professor), Department of Oral Medicine and Radiology, Malla Reddy Institute of Dental Sciences, Suraram 500055, Telangana, India. maithreya.prashanth@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (*WJCC, World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

*WJCC* mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for *WJCC* as 1.337; IF without journal self cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The *WJCC*’s CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Lin-YuTong Wang; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

*World Journal of Clinical Cases*

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE

February 16, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS

https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS

https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT

https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE

https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS

https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION

https://www.f6publishing.com
Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report

Juan Wang, Yong-Sheng Gao, Kun Xu, Xiao-Dong Li

Abstract

BACKGROUND
The prognosis of refractory extranodal natural killer/T-cell lymphoma (ENKTL) is poor. Recent data have indicated that immune checkpoint blockade with a programmed cell death protein-1 (PD-1) antibody in combination with administration of histone deacetylase inhibitors represents a potentially effective treatment strategy. Compared with PD-1 antibodies, programmed death-ligand 1 antibodies have fewer side effects. Here, we present a rare case of a patient with refractory metastatic ENKTL who achieved sustained remission of approximately 10 mo with minor adverse effects after combination therapy with atezolizumab, chidamide, and radiotherapy.

CASE SUMMARY
A 56-year-old woman underwent resection of a tumour in her left nasal cavity and was diagnosed with ENKTL (nasal type). Medical examination revealed tumours observed in the bilateral nasal mucosa, the subcutaneous soft tissue of the inner side of the left eye, the soft tissue of the nasopharynx, the bilateral tonsils, and the left preauricular, right hilar, bilateral neck lymph nodes and bone marrow. However, tomography/computed tomography showed increased metabolism of...
CONCLUSION

The outcome in this case suggests that the combination of atezolizumab, chidamide, and radiotherapy is a promising regimen for treating refractory metastatic ENKTL following chemotherapy treatment failure.

Key Words: Long-term remission; Refractory metastatic extranodal natural killer/T-cell lymphoma; Histone deacetylase; Programmed death-ligand 1 antibody; Radiotherapy; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: extranodal natural killer/T-cell lymphoma (ENKTL) is a subtype of non-Hodgkin lymphoma with poor outcomes because ENKTL cells express high levels of P-glycoprotein that mediate tumour multidrug resistance. Furthermore, the standard treatment modality for chemotherapy-resistant ENKTL remains debated. We have experienced a patient with refractory metastatic ENKTL who was resistant to conventional DDGP chemotherapy. Following systemic therapy with atezolizumab and chidamide in combination with local radiotherapy, the patient achieved sustained remission of approximately 10 mo with minor adverse effects.

INTRODUCTION

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a distinct subtype of mature T-cell and NK-cell lymphoma that is prevalent in regions of East Asia and South America[1-3]. ENKTL progresses rapidly and has a poor prognosis. Although options for therapy continue to evolve, their curative effects remain unsatisfactory. Because ENKTL cells express high levels of P-glycoprotein that mediate tumour multidrug resistance, conventional chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) have poor outcomes. Thus, nonanthracycline-based chemotherapy has become the main therapeutic strategy. However, in patients for whom L-asparaginase-based regimens are ineffective, progression-free survival (PFS) after relapse or first progression was only 4.1 mo[4].

Recently, several studies have reported that HDAC inhibitors (HDACis) combined with anti-death protein-1 (PD-1) immunotherapy showed encouraging efficacy, thus representing a new treatment strategy for relapsed/refractory (r/r) ENKTL[5,6]. However, the combination of death-ligand 1 (PD-L1) antibody and HDACi for r/r ENKTL has not yet been investigated. Here, we report the case of a patient with refractory metastatic ENKTL who achieved a durable response following systemic therapy with PD-L1 antibody and chidamide in combination with local radiotherapy.

CASE PRESENTATION

Chief complaints

A 56-year-old woman had been diagnosed with ENKTL (nasal type) for one month.
History of present illness
The patient underwent resection of a tumour in her left nasal cavity and was diagnosed with ENKTL (nasal type). Before being transferred to our hospital, she accepted her first cycle chemotherapy with CHOPE (cyclophosphamide 1000 mg Day 1 + vincristine 2 mg Day 1 + epirubicin 100 mg Day 1 + etoposide 100 mg Days 1-3 + prednisone acetate 100 mg Days 1-5) and developed grade IV myelosuppression.

History of past illness
The patient had a free previous medical history.

Personal and family history
Personal and family history was non-contributory.

Physical examination
The patient’s temperature was 36.4 °C, heart rate was 102 beats/min, respiratory rate was 25 breaths/min, and blood pressure was 122/95 mmHg. The clinical examination revealed facial strut and pain.

Laboratory examinations
The tumour cells stained positive for CD3, CD56, TIA-1, and Ki-67 (approximately 40%) but were negative for CD20 (Figure 1). Bone marrow examination was performed. Flow cytometry revealed 0.71% NK cells with the following abnormal immunophenotypes: CD2+, CD7+, CD56+, CD94+, CD161+, CD5-, CD16-, and CD8+/-.

Imaging examinations
Positron emission tomography/computed tomography (PET/CT) was performed for staging, and increased 18F-fluorodeoxyglucose (FDG) uptake was observed in the bilateral nasal mucosa, the subcutaneous soft tissue of the inner side of the left eye, the soft tissue of nasopharynx, the bilateral tonsils, and the left preauricular, right hilar, and bilateral neck lymph nodes. These patterns were consistent with the infiltration of malignant lymphoma (Figure 2).

FINAL DIAGNOSIS
The patient was diagnosed with ENKTL (nasal type). Disease was evaluated as Ann Arbor stage IVE A, the prognostic index for NK/T-cell lymphoma, including Epstein-Barr virus DNA load (PINK-E), was calculated as 3, and disease was classified as high risk.

TREATMENT
Radiotherapy, chidamide, and nivolumab were concurrently administered. The target volume included the partial frontal sinus, the right maxillary sinus, all ethmoid sinuses, the sphenoid sinus, the left orbit and eye contents, the left maxillary sinus, the nasopharynx, the left preauricular lymphoid drainage area, and the bilateral neck level I, 2, 3, 4, and 5 Lymphatic drainage areas. The radiation dose was 50 Gy/25 fractions. The patient developed transient rash on the third day after nivolumab treatment and grade 4 thrombocytopenia following the first cycle of combination therapy. Therefore, the PD-1/PD-L1 inhibitor was changed to atezolizumab for subsequent immuno-therapy after her haemogram recovered.

OUTCOME AND FOLLOW-UP
After four cycles of chidamide and atezolizumab, PET/CT showed slightly higher metabolism of the nasal cavity. Treatment was continued as planned. Fortunately, PET/CT showed no obvious FDG uptake after 11 cycles of combination therapy with chidamide and atezolizumab (Figure 2). Grade 3 adverse events, including neutropenia and thrombocytopenia, were manageable and resolved during maintenance treatment.
ENKTL is a subtype of non-Hodgkin lymphoma with poor outcome. The standard treatment modality for refractory ENKTL is still debated, especially for chemotherapy-resistant tumours[4]. Here, we present the case of a patient with refractory metastatic ENKTL who was resistant to conventional DDGP chemotherapy. Following systemic therapy with a PD-L1 inhibitor and chidamide in combination with local radiotherapy, the patient achieved sustained remission of approximately 10 mo with minor adverse effects.

Previous studies suggested that NKTL was resistant to anthracycline[7]. Thus, pegaspargase, gemcitabine, or other non-anthracycline-based chemotherapy regimens are generally used for the first-line treatment of patients with newly diagnosed refractory NKTL[8,9]. Additionally, as described in previous reports, allogeneic stem cell transplantation (allo-SCT) may be beneficial for patients with ENKTL[10,11]. However, PFS in the subset of patients who maintained remission following allo-SCT was only approximately 10.0 mo. There has been no randomized, prospective study to evaluate the safety and efficacy of allo-SCT in ENKTL[12].

Recently, radiotherapy, PD-1 inhibitors, and HDACis (alone or in combination) have shown promising efficacy in treating r/r ENKTL. Chidamide is a novel benzamide-type HDACi that can selectively block HDAC1, 2, 3, and 10[13]. Recent data demonstrated that chidamide induced growth inhibition and apoptosis in NK/T lymphoma cells[14]. A phase II clinical trial of chidamide for r/r peripheral T-cell lymphoma showed median PFS and overall survival of 2.1 and 21.4 mo, respectively [15]. In this study, 16 ENKTL patients were enrolled and showed lower response rates compared with other studies: one patient achieved a complete response (CR), and two patients achieved partial responses (PRs).

PD-1/PD-L1 inhibitors are additional new agents for the treatment of r/r ENKTL. In previous reports (Table 1), combining PD-1 antibody with chemotherapy or chidamide obtained satisfactory results, and most of the cases achieved complete response and sustained curative effects[16-21]. The anti-PD-1 antibody (sintilimab) plus chidamide regimen was evaluated in a phase 1b/II clinical trial[22], where the CR rate was 44.4% in 41 r/r-NKTCL patients. A previous study demonstrated that anti-
Table 1 Reports regarding the application of death protein-1/death-ligand 1 inhibitors in refractory or relapsed extranodal natural killer/T-cell lymphoma

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Number of cases</th>
<th>Age mean year (range)</th>
<th>Gender</th>
<th>Treatment</th>
<th>Stage</th>
<th>Response</th>
<th>OS or PFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>McGehee et al [16] 2021</td>
<td>1</td>
<td>72</td>
<td>1 M</td>
<td>Pembrolizumab plus RT</td>
<td>IV</td>
<td>CR</td>
<td>33 mo, alive</td>
</tr>
<tr>
<td>Du et al [17] 2020</td>
<td>3</td>
<td>52 (51-54)</td>
<td>3 M</td>
<td>PD-1 antibody, plus Chidamide, etoposide, and thalidomide</td>
<td>1 (33.3%) IV; 1 (33.3%) III; 1 (33.3%) I</td>
<td>2 (66.7%) CR; 1 (33.3%) PD</td>
<td>-</td>
</tr>
<tr>
<td>Kwong et al [18] 2017</td>
<td>7</td>
<td>49 (31-68)</td>
<td>7 M</td>
<td>Pembrolizumab</td>
<td>2 (71.4%) IV; 2 (28.6%) III</td>
<td>5 (71.4%) C; 2 (28.6%) PR</td>
<td>-</td>
</tr>
<tr>
<td>Li et al [19] 2018</td>
<td>7</td>
<td>47 (17-61)</td>
<td>4 M; 3 F</td>
<td>Pembrolizumab</td>
<td>2 (28.6%) IV; 3 (42.9%) III; 1 (14.3%) I III; 1 (14.3%) IE</td>
<td>2 (28.6%) CR; 2 (28.6%) PR</td>
<td>5 mo OS; 4.8 mo PFS</td>
</tr>
<tr>
<td>Diab et al [20] 2021</td>
<td>1</td>
<td>82</td>
<td>M</td>
<td>Pembrolizumab</td>
<td>IV</td>
<td>CR</td>
<td>21 mo, alive</td>
</tr>
<tr>
<td>Lai et al [21] 2017</td>
<td>1</td>
<td>37</td>
<td>F</td>
<td>Pembrolizumab</td>
<td>IV</td>
<td>CR</td>
<td>-</td>
</tr>
<tr>
<td>Gao et al [22] 2020</td>
<td>41</td>
<td>48 (20-72)</td>
<td>27 M; 14 F</td>
<td>Sintilimab plus chidamide</td>
<td>26 (70.3%) IV; 15 (29.7%) Non-IV</td>
<td>16 (44.4%) CR; 5 (13.9%) PR</td>
<td>-</td>
</tr>
<tr>
<td>Kim et al [24] 2020</td>
<td>21</td>
<td>≤ 60 16; &gt; 60 5</td>
<td>13 M; 8 F</td>
<td>Avelumab</td>
<td>-</td>
<td>5 (23.8%) CR; 3 (14.3%) PR</td>
<td>-</td>
</tr>
</tbody>
</table>

OS: Overall survival; PFS: Progression-free survival; M: Male; F: Female; Non-IV: Non-stage IV patients; RT: Radiotherapy.

PD-L1 antibodies have better efficacy and fewer adverse effects [23]. In particular, an open-label phase 2 study demonstrated that a PD-L1 antibody as a single agent induced tumour remission in a subset of patients. CRs were observed in 24% of patients, and the overall response rate was 38%; the study was terminated because of a lower than expected response rate [24]. Five responders in this study continued to show sustained responses, and the only adverse events observed were grades 1 or 2. However, to our knowledge, there have been no case reports evaluating the effects of PD-L1 antibody for r/r-ENKTL patients who could not tolerate previous treatment with PD-1 antibody.

Recently, multiple lines of evidence have demonstrated that HDACis could enhance the therapeutic effects of PD-1 antibodies [25,26]. Epigenetic modification could regulate T cell trafficking and reactivation, thus enhancing the efficacy of the PD-1 antibody. A few case reports suggested that the combination of PD-1 antibodies and HDACis might be effective in patients with refractory ENKTL [5,6]. However, the antitumour effect of combination therapy with PD-L1 antibody and chidamide has not been demonstrated for refractory ENKTL. The patient described here was successfully treated with local radiotherapy and systemic therapy with chidamide and PD-L1 antibodies. Evaluation 10 mo following the end of radiation therapy showed a sustained CR. We presume that the sustained therapeutic efficacy observed in this patient may result from synergistic effects of PD-L1 antibody, chidamide, and local radiotherapy. Studies with larger numbers of patients are needed to evaluate the efficacy and safety of this combination therapy regimen for refractory ENKTL.

**CONCLUSION**

We present a rare case of a patient with refractory ENKTL who was successfully treated with a combination of radiotherapy, chidamide, and PD-L1 antibody. Additional evidence is needed to evaluate the potential activity and safety of this regimen.
Figure 2 Imaging at diagnosis, after four cycles of chemotherapy with DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase), and 10 mo posttreatment with death-ligand 1 antibody and chidamide. A: Positron emission tomography showing hypermetabolism in the bilateral nasal mucosa, the subcutaneous soft tissue of the inner side of the left eye, the soft tissue of the nasopharynx, the bilateral tonsil, and the left preauricular, bilateral neck, and right hilar lymph nodes; B: After four cycles of DDGP chemotherapy, increased metabolism of the lesions was observed except in the right hilar lymph nodes; C: Patient achieved sustained remission for approximately 10 mo.

ACKNOWLEDGEMENTS

We thank the patient and her family for providing signed informed consent.

REFERENCES


Wang J et al. Combination therapy with atezolizumab and chidamide

Medicine (Baltimore) 2021; 100: e24824 [PMID: 33725836 DOI: 10.1097/MD.00000000000024824]


Wang J et al. Combination therapy with atezolizumab and chidamide


